Sign Up Today and Learn More About Rakuten Aspyrian Stock
Invest in or calculate the value of your shares in Rakuten Aspyrian or other pre-IPO companies through EquityZen's platform.
Rakuten Aspyrian Stock (RAAS)
Tumor-targeted precision therapies
About Rakuten Aspyrian Stock
Founded
2010
Headquarters
San Diego, CA, US
Total Funding
352M
Industries
Software, Artificial Intelligence, Data and Analytics
Rakuten Aspyrian is a privately funded clinical stage biotechnology company developing tumor-targeted precision therapies based on its proprietary platform Photoimmunotherapy. Photoimmunotherapy combines key advantages of antibody-mediated targeting of the cancer cells to achieve high tumor specificity, together with laser-activation of a biophysical mechanism that induces rapid cancer cell death with precision. Treatments with the Photoimmunotherapy platform lead to targeted and rapid tumor cell death by necrosis, with minimal effects on normal tissue. Rakuten Aspyrian is studying Photoimmunotherapy for use as a monotherapy and in combination with other drugs. Founded in 2013, the company is based in San Diego, California.
Rakuten Aspyrian Press Mentions
Stay in the know about the latest news on Rakuten Aspyrian
Phthalocyanine dye compounds, conjugates and methods of use thereof
patents • Nov 19, 2024
Methods for local and systemic treatment of cancers, tumors and tumor cells
patents • Nov 19, 2024
Phthalocyanine dye compounds, conjugates and methods of use thereof
patents • Nov 02, 2024
Methods for enhancing immunity and tumor treatment
patents • Nov 02, 2024
Engineered interleukin-15 polypeptides, complexes and uses thereof
patents • Sep 26, 2024
Join now and verify your accreditation status to gain access to:
- Rakuten Aspyrian current valuation
- Rakuten Aspyrian stock price
- Available deals in Rakuten Aspyrian and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading Rakuten Aspyrian Stock
How to invest in Rakuten Aspyrian stock?
Accredited investors can buy pre-IPO stock in companies like Rakuten Aspyrian through EquityZen funds. These investments are made available by existing Rakuten Aspyrian shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Rakuten Aspyrian stock?
Shareholders can sell their Rakuten Aspyrian stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
